TrumpRx portal directs cash‑paying patients to manufacturer discounts; Eli Lilly signs on

White House portal aims to steer cash-paying patients to maker discounts

President Donald Trump launches TrumpRx, a direct‑to‑consumer website designed to steer U.S. patients who pay cash toward drugmakers’ own discount pages, and Eli Lilly & Co. is among the companies agreeing to participate. The site does not sell medicines itself but serves as a central directory linking consumers to manufacturers offering reduced prices, a model already in partial use by firms such as Lilly and Novo Nordisk. The administration frames the effort as a way to lower out‑of‑pocket costs for people without insurance or with limited coverage.

Lilly backs expanded direct sales model via TrumpRx

Eli Lilly’s participation in the White House initiative underscores the company’s push into direct‑to‑patient offerings, particularly for obesity treatments. Chief Executive Dave Ricks says Lilly was an early mover in selling such therapies directly to patients and that TrumpRx “is taking that and expanding it across the industry,” adding “we’re all for that.” The company signs a voluntary participation agreement under a broader administration effort that seeks to link U.S. prices to the lowest international prices through a “most favored nation” approach and to offer negotiated discounts to Medicaid patients.

Lilly’s role signals a broader industry shift but raises questions about who benefits. TrumpRx targets cash‑paying consumers who opt out of insurance, and while manufacturers tout steep reductions from list prices, analysts note many insured patients already pay lower net prices once rebates and concessions are applied. It remains unclear how much additional relief the platform provides to people with private insurance or government coverage, and the reach of discounted access depends on whether consumers can and will pay cash rather than use their plans.

Other industry participants and pricing examples

The administration says it has negotiated participation agreements with Lilly, Novo Nordisk and at least 14 other drugmakers. Novo Nordisk, for example, agrees to list Ozempic on TrumpRx at $350 per month — roughly a third of its retail list price — a figure the White House highlights as an example of the platform’s potential savings.

Researchers caution on headline reductions

Policy analysts at Georgetown’s Medicare Policy Initiative and others note list prices can differ substantially from the net prices manufacturers already provide to payers, suggesting the program’s advertised cuts may overstate savings for some groups. The voluntary nature of the program and the focus on cash sales leave open questions about long‑term impact on access and overall drug pricing.